Subscribe To
FMTX / Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
FMTX News
By Invezz
September 2, 2022
Forma Therapeutics shares jump 50%; here is why
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk. more_horizontal
By Seeking Alpha
March 1, 2022
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
March 1, 2022
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Seeking Alpha
March 1, 2022
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript
Forma Therapeutics Holdings' (FMTX) CEO Frank Lee on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Business Wire
February 23, 2022
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on Marc more_horizontal
By Business Wire
February 23, 2022
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on Marc more_horizontal
By Business Wire
February 23, 2022
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on Marc more_horizontal
By Business Wire
October 7, 2021
Forma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell more_horizontal